The cell & gene landscape is ripe with big promises backed by evolving tech, fresh talent with splashes of funding and M&A catching headlines as therapies roll forward. But how are the experts doing it in 2023? What are the biggest scientific advancements — and best strategies for investment, manufacturing and commercial access? Join us as we explore the field’s future — and examine past safety issues — with a series of sessions geared toward furthering cell & gene drug development.
State of the industry briefing - Tim Hunt: CEO, ARM
Next-gen viral vectors take the spotlight as safety frets persist
The future is now: CGTx innovation, challenges, and perspectives
The need for speed in CGT manufacturing: Increasing throughput and efficiency through process innovation, automation, and digitization
The price is right: Approvals & market access in 2023
Moving clinical development forward in 2023
ARM’S annual update on progress in the CGTx Sector
In this session you will hear about:
Established AAVs have helped birth a new era of drugs, while also underscoring safety threats that can torpedo clinical-stage development projects. Now a new generation of vectors are coming along to keep the development work on track, with improvements in vector tech that promise widespread adoption — if it works.
Despite recent economic challenges, innovators are working tirelessly to develop cutting-edge advancements that have the potential to revolutionize patient care. From state-of-the-art technologies to groundbreaking scientific breakthroughs, the need for increased efficiency, enhanced safety, and shorter time-to-market has never been more critical. Join our panel of experts as they discuss the latest healthcare advancements, their transformative impact on patient outcomes, and strategies for accelerating the delivery of these life-changing treatments.
Manufacturing is one of the biggest obstacles for cell and gene therapy companies, requiring significant investment and highly specialized processes that can be very complex and difficult to develop and maintain in-house. With the paradigm shift from ‘Make’ to ‘Buy’ for advanced therapy manufacturing, innovator companies need to carefully consider their choice of CDMO partner for their manufacturing needs to ensure adequate, on-time capacity for the patients who desperately need these life-changing therapies.
Payers and purchasers continue to grapple with complex discussions around drug pricing, duration of effect, and reimbursement mechanisms, which are creating barriers to access. In this session, our experts share their insights on how stakeholders across the treatment development continuum can collaborate to develop evidence and streamline these processes to enhance access.
Clinical trials are essential for developing innovative and life-saving treatments for patients. However, the process can be challenging and complex for developers. In this session, our panel of experts will explore the latest strategies for navigating the complexities of clinical trial execution and share valuable insights into the cutting-edge advancements that are driving the future of healthcare innovation.
